Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06910657 · ClinicalTrials.gov registry record · Phase 1
IDOV-Immune for Advanced Solid Tumors
A Phase 1 study of Breast Cancer and Colorectal Cancer, sponsored by ViroMissile.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
- 6
- Study locations
NCT06910657: Recruiting Phase 1 study of Breast Cancer and Colorectal Cancer, sponsored by ViroMissile.
NCT06910657 is a Phase 1 study of Breast Cancer and Colorectal Cancer that is actively recruiting participants, run by ViroMissile. The registered enrollment target is 78 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06910657, a Phase 1 study of Breast Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by ViroMissile.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potential to stimulate the immune system to fight the tumor. The purpose of this study is to determine the safety of IDOV-Immune, how well it is tolerated, and to identify the highest dose that can be safely given. Researchers will also study how the drug behaves in the body, how the immune system responds to it, and whether it shows any signs of shrinking tumors. Participants will receive a single intravenous (IV) infusion of IDOV-Immune and will be closely monitored for side effects and any changes in their cancer. This study is being conducted at multiple sites in the United States and Australia.
Primary Outcome
The number and proportion of participants experiencing dose-limiting toxicities (DLTs), assessed by dose level during the DLT evaluation period. DLTs are defined per protocol-specified criteria and graded according to CTCAE.
Conditions Studied
Interventions
- BIOLOGICAL IDOV-Immune (oncolytic vaccinia virus)
Study Locations (6)
Texas
- MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics - San Antonio
New South Wales
- Royal North Shore Hospital - Saint Leonards
- Westmead Hospital - Westmead
Missouri
- Washington University School of Medicine - St Louis
Victoria
- The Alfred Hospital - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 1 |
What NCT06910657 shows while recruiting
NCT06910657 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which IDOV-Immune (oncolytic vaccinia virus) is the first listed.
NCT06910657 lists 6 locations in 4 states (Texas, New South Wales, Missouri).
Frequently Asked Questions
What is clinical trial NCT06910657 about?
NCT06910657 is a clinical study titled "IDOV-Immune for Advanced Solid Tumors". This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potenti...
What is the current status of trial NCT06910657?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2025-08-25. Estimated completion is 2027-05-31.
What conditions does trial NCT06910657 study?
This clinical trial studies the following conditions: Breast Cancer, Colorectal Cancer, Ovarian Cancer, Pancreatic Cancer, Melanoma.
What interventions are being tested in trial NCT06910657?
The interventions under investigation include: IDOV-Immune (oncolytic vaccinia virus) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06910657?
This trial is sponsored by ViroMissile, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06910657 being conducted?
This trial has 6 study locations across Missouri, Texas, New South Wales, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06910657's enrollment target sits among peer trials
78 662nd of 1224 higher than 556 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI